Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds hormone or other secreted growth regulatory factor,...
Reexamination Certificate
2008-06-06
2010-11-23
Landsman, Robert (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds hormone or other secreted growth regulatory factor,...
C514S012200, C530S350000, C530S399000
Reexamination Certificate
active
07837999
ABSTRACT:
A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibiting improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, a targeting ligand, or another active or therapeutic compound. IGF1 variants were shown to have improved ability to induce skeletal muscle hypertrophy relative to native IGF1.
REFERENCES:
patent: WO/90/15142 (1990-12-01), None
patent: 0742228 (1996-11-01), None
Jansson et al., 1997, “Structural changes in insulin-like growth factor (IGF) I mutant proteins affecting binding kinetic rates to IGF binding protein 1 and IGF-I receptor.” Biochemistry Apr. 8;36(14):4108-17.
Jansson et al., 1998, “The insulin-like growth factor (IGF)binding protein 1 binding epitope on IGF-I probed by heteronuclear NMR spectroscopy and mutational analysis.” J Biol Chem. Sep. 18;273(38):24701-7.
Bayne et al., 1989, “The C region of human insulin-like growth factor (IGF) I is required for high affinity binding to the type 1 IGF receptor.” J Biol Chem. Jul. 5;264(19):11004-8.
Heding et al., 1996, “Biosensor measurement of the binding of insulin-like growth factors I and II and their analogues to the insulin-like growth factor-binding protein-3.” J Biol Chem. Jun. 14;271(24):13948-52.
Daly Thomas J.
Glass David J.
Papadopoulos Nicholas J.
Yancopoulos George D.
Dang Ian
Gregg, Esq. Valeta
Landsman Robert
Regeneron Pharmaceuticals Inc.
Yokoyama, Esq. Izumi
LandOfFree
Method of increasing muscle mass with IGF-1 fusion polypeptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of increasing muscle mass with IGF-1 fusion polypeptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of increasing muscle mass with IGF-1 fusion polypeptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4177365